Research at Whitman-Walker began more than three decades ago with industry-sponsored trials to test novel treatments for HIV. Since then our work has expanded to include both clinical and observational HIV research, as well as both foundation- and NIH-funded research studies on which we are the lead site. In partnership with Whitman-Walker Health, our affiliated federally qualified health center (FQHC), the Institute is proud to be a world-class leader in clinical and applied research, as reflected in milestones such as a recent NIH capital award for a state-of-the-art community-centered biomedical research facility to accelerate breakthroughs in HIV prevention and treatment at Whitman-Walker’s new flagship site in Southeast DC.
We contribute to Whitman-Walker’s mission by serving communities both locally and nationally who have been historically marginalized in health care and research: in the past 10 years, we have recruited more than 5,600 participants into research studies, of whom nearly half (47%) identify as Black and 12% as Hispanic/Latino, 50% are living with HIV, and 8.4% identify as transgender. Our growing portfolio of work is led by a diverse team of 11 expert investigators and supported by more than 40 staff, including dedicated administrative and data teams.